EFFECTIVENESS OF INTRALESIONAL CORTICOSTEROID INJECTION FOR NODULOCYSTIC ACNE : A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
Keywords:
triamcinolone acetonide, intralesional injection, nodulocystic acne, Systematic Review, efficacyAbstract
Introduction: Nodulocystic acne represents the most severe phenotype of acne vulgaris, associated with significant physical and psychosocial morbidity. Intralesional corticosteroid injection (ILC) has been used clinically for >60 years, yet systematic evidence synthesis remains limited. This review aims to evaluate the efficacy, safety, and optimal concentration of ILC for nodulocystic acne.
Methods: Systematic review conducted according to PRISMA 2020 guidelines. Included studies comprised RCTs, quasi-RCTs, comparative cohort studies, pre-post studies, and case series (n≥5). Risk of bias was assessed using Cochrane RoB 2.0 and Newcastle-Ottawa Scale.
Results: Fifteen studies comprising 1,247 subjects were included. Triamcinolone acetonide (TA) at concentrations of 0.63–5 mg/mL demonstrated consistent efficacy, with symptomatic improvement onset within 24–72 hours and median lesion resolution of 4.6–8.1 days depending on modality. Lesion diameter reduction reached 65–85% by Day 7. Mean VAS pain score reduction was 2.27 points (p<0.0001) with cryoanesthesia. TA-loaded detachable microneedle patch (DMN) technology demonstrated faster resolution (median 4.6 vs 8.1 days; p<0.05). Betamethasone phosphate showed no superiority over saline control (p=0.16). Incidence of cutaneous atrophy and hypopigmentation was <5% with appropriate injection technique.
Discussion: TA at 0.63–2.5 mg/mL constitutes the most effective and safe ILC agent. Technical innovations (cryoanesthesia, DMN) significantly improve tolerability and accessibility. Major limitations include scarcity of high-quality RCTs, design heterogeneity, and absence of longitudinal data.
Conclusion: Intralesional triamcinolone acetonide injection at 0.63–2.5 mg/mL represents an effective, safe, and rapidly responsive therapeutic modality for nodulocystic acne. Large-scale multicenter RCTs with ≥6 months follow-up are urgently required.
References
Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol. 1983;119(6):480-481. doi:10.1001/archderm.1983.01650300018008. PMID: 6222700. Available at: https://pubmed.ncbi.nlm.nih.gov/6222700/
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037. PMID: 26897386. Available at: https://pubmed.ncbi.nlm.nih.gov/26897386/
National Guideline Alliance (UK). Intralesional corticosteroids for the treatment of individual acne vulgaris lesions. In: Acne Vulgaris: Management [Internet]. London: National Institute for Health and Care Excellence (NICE); 2021 Jun. NBK573050. Available at: https://www.ncbi.nlm.nih.gov/books/NBK573050/
Park SJ, Shin SH, Koh YG, Kim GH, Rho NK, Park KY. Cold anesthesia for pain reduction during intralesional steroid injection for nodulocystic acne. J Cosmet Dermatol. 2023 Dec;22(12):3375-3378. doi:10.1111/jocd.15829. PMID: 37218601. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15829
Thantaviriya S, Kamanamool N, Sansureerungsikul T, Udompataikul M, Wanichwecharungruang S, Rojhirunsakool S. Efficacy and Safety of Detachable Microneedle Patch Containing Triamcinolone Acetonide in the Treatment of Inflammatory Acne. Clin Cosmet Investig Dermatol. 2023 Jun 5;16:1431-1441. doi:10.2147/CCID.S411378. PMID: 37303985. Available at: https://pubmed.ncbi.nlm.nih.gov/37303985/
ACOM Labs. Intralesional Injections of Triamcinolone for Acne Vulgaris [Internet]. ClinicalTrials.gov Identifier: NCT06170593. Status: Completed [2022–2023]. Available at: https://clinicaltrials.gov/study/NCT06170593
ACOM Labs. Self-Administered Intralesional Injections for Acne [Internet]. ClinicalTrials.gov Identifier: NCT06186596. Status: Completed [2022–2023]. Available at: https://clinicaltrials.gov/study/NCT06186596
Kambhampati S, Bohnert K, Ascha M, Ascha M, Ferris LK. Intralesional triamcinolone for inflammatory acne: a comparative study of dose efficacy and investigation of a novel injection assistance device to enable self-administration of intralesional therapy. J Dermatolog Treat. 2025;36(1). doi:10.1080/09546634.2025.2504656. Available at: https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2504656
Hayward WA, Reynolds KA, Mesinkovska NA. Dermatologist Use of Intralesional Triamcinolone in the Treatment of Acne. J Clin Aesthet Dermatol. 2021 Jan;14(1):44-48. PMID: 33584918. Available at: https://jcadonline.com/intralesional-triamcinolone-acne-treatment/
Lee S, Park J, Kim J. Steroid Injection Treatment for Nodulocystic Acne: A Literature Review. Dermatological Reviews. 2025;6:e70021. doi:10.1002/der2.70021. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/der2.70021
Ravindran J, Suresh A, Chakiath JA, Mardavada H. Uncommon Complication of a Common Therapy: Sterile Abscess After Triamcinolone Injection for Acne. Clin Exp Dermatol. 2025. doi:10.1177/30499240251357386. Available at: https://journals.sagepub.com/doi/10.1177/30499240251357386
Sharma R, Gupta M, Rani R. Delineating injectable triamcinolone-induced cutaneous atrophy and therapeutic options in 24 patients—a retrospective study. Indian Dermatol Online J. 2022;13(2):199-206. doi:10.4103/idoj.idoj_483_21. PMID: 35287381. Available at: https://pubmed.ncbi.nlm.nih.gov/35287381/
Park J, Chang M. Eyelid fat atrophy and depigmentation after an intralesional injection of triamcinolone acetonide to treat chalazion. J Craniofac Surg. 2017;28(3):e198-e199. doi:10.1097/SCS.0000000000003367. PMID: 28350665. Available at: https://pubmed.ncbi.nlm.nih.gov/28350665/
Zaenglein AL, Thiboutot DM, Baldwin HE, et al. Guidelines of care for the management of acne vulgaris (AAD 2024 Update). J Am Acad Dermatol. 2024;90(5):1167.e1-1167.e18. doi:10.1016/j.jaad.2023.12.048. Available at: https://www.jaad.org/article/S0190-9622(23)03389-3/fulltext
Wiraputranto A, Sitohang IBS, Budianti WK, Sampurna AT. Acne Vulgaris Medicament Management in Indonesia and the Efficacy of Various Therapeutic Regimens. Open Access Maced J Med Sci. 2023 Apr 14;11(F):245-252. doi:10.3889/oamjms.2023.11576. Available at: https://oamjms.eu/index.php/mjms/article/download/11576/8579/112149
Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol. 1995;20(5):363-370. doi:10.1111/j.1365-2230.1995.tb01346.x. PMID: 8697383. Available at: https://pubmed.ncbi.nlm.nih.gov/8697383/
Usatine RP, Pfenninger JL. Intralesional Drug Administration. In: Dermatologic and Cosmetic Procedures in Office Practice. Philadelphia: Elsevier Saunders; 2012. p.145-160. Available at: https://www.sciencedirect.com/topics/nursing-and-health-professions/intralesional-drug-administration
Tan JKL, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015 Jul;172 Suppl 1:3-12. doi:10.1111/bjd.13462. PMID: 25597339. Available at: https://pubmed.ncbi.nlm.nih.gov/25597339/
Pace BF. Triamcinolone hexacetonide as adjunctive therapy in cystic acne. South Med J. 1968 Nov;61(11):1204-1206. doi:10.1097/00007611-196811000-00017. PMID: 4248001. Available at: https://pubmed.ncbi.nlm.nih.gov/4248001/
Rahimi H, Mehri M, Hamzelou S. Living With Acne Vulgaris in Young Adults: A Holistic Examination of Its Impact on Quality of Life Using the Dermatology Life Quality Index (DLQI). Dermatol Res Pract. 2024. PMC11806962. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806962/
Sukmawati D, Mauluddina H, Wijaya I, et al. Microbiomes in Acne Vulgaris and Their Susceptibility to Antibiotics in Indonesia: A Systematic Review and Meta-Analysis. Antibiotics. 2023;12(1):145. doi:10.3390/antibiotics12010145. PMID: 36671346. Available at: https://www.mdpi.com/2079-6382/12/1/145
Lee SJ, Hyun MY, Park KY, Kim BJ. A tip for performing intralesional triamcinolone acetonide injections in acne patients. J Am Acad Dermatol. 2014 Oct;71(4):e127-8. doi:10.1016/j.jaad.2014.04.030. PMID: 25219726. Available at: https://www.jaad.org/article/S0190-9622(14)01383-8/fulltext
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71. PMID: 33782057. Available at: https://www.bmj.com/content/372/bmj.n71
Higgins JPT, Thomas J, Chandler J, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane; 2023. Available at: www.training.cochrane.org/handbook
PERDOSKI. Clinical Practice Guidelines for Dermatologists and Venereologists in Indonesia. Jakarta: Indonesian Society of Dermatology and Venereology (PERDOSKI); 2021. pp. 343-346.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Rielyana Lumban Gaol (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
